Cationic Lipid Nanoparticles for Efficient Low-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cationic lipid compounds for nucleic acid delivery face challenges in achieving high transfection efficiency, low cytotoxicity, and sustained expression, complicating their production and safety, which limits their clinical application.
Innovation Solution
Development of novel cationic lipid compounds, such as YK-009, YK-003, YK-006, YK-008, and YK-011, with specific alkyl and alkylene structures, formulated into nanoparticle compositions with optimized ratios of neutral, structured, and polymer-conjugated lipids, enhancing delivery efficiency and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cationic lipid compounds are used for nucleic acid delivery, then transfection efficiency can be achieved, but cytotoxicity increases and sustained expression is compromised
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as alkyl chain length (L1: C6-C15, preferably C8-C12), alkylene bridge structures (G1: C1-C6, G2: C2-C8, G3: C1-C3), and head group composition. These parameter changes optimize the balance between transfection efficiency and cytotoxicity, achieving compounds with enhanced safety profiles while maintaining delivery effectiveness.
Solution Approach 2:
The invention creates composite lipid nanoparticle formulations combining the novel cationic lipid with neutral lipids (e.g., DSPC, DOPE), structured lipids (e.g., cholesterol), and PEG-conjugated lipids. This composite approach synergistically improves transfection efficiency while reducing cytotoxicity through the complementary properties of different lipid components.
2Reliability
If complex lipid nanoparticle compositions are used to improve delivery, then transfection efficiency increases, but production complexity and toxicity increase
Solution Approach 1:
The patent optimizes the molar ratios of lipid components in the nanoparticle formulation, specifying ranges such as cationic lipid:neutral lipid:structured lipid:PEG-lipid ratios. This parameter optimization achieves effective delivery with simplified production protocols, reducing the need for complex multi-step manufacturing processes while maintaining high transfection efficiency.
3Reliability
If existing cationic lipid compounds are used, then some transfection activity is achieved, but expression levels and sustained expression in animals are insufficient
Solution Approach 1:
The patent modifies structural parameters of the cationic lipid including the hydrophobic tail configurations (L1 linear alkyl C6-C15, L2 branched alkyl C12-C25), alkylene bridge lengths (G1: C1-C6, G2: C2-C8, G3: C1-C3), and charge density. These changes enhance both the magnitude and duration of gene expression in animal models, achieving sustained therapeutic effects.
Data Source
Figure 1a~3c
Figure 4a~5
Figure 6~7
AI summary
Provided in the present disclosure are a compound of formula (I), or an N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer thereof. Further provided are a composition containing the aforementioned compound, and the use thereof in the delivery of a therapeutic agent or prophylactic agent.